Chia-chi Chen

Kaohsiung, KHQ 82445, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

PTC124 promotes mutation site-dependent readthrough of STK11 nonsense mutations and restores tumor suppressor function.

PTC124 promotes mutation site-dependent readthrough of STK11 nonsense mutations and restores tumor suppressor function.

Journal: BBA advances

Published: March 30, 2026

Regulation of autophagy by the p53 family and the implications for cancer therapies.

Regulation of autophagy by the p53 family and the implications for cancer therapies.

Journal: Discover oncology

Published: January 24, 2026

CLEC3B (tetranectin) expression is associated with vascular localization and tumor aggressiveness in breast cancer.

CLEC3B (tetranectin) expression is associated with vascular localization and tumor aggressiveness in breast cancer.

Journal: International journal of medical sciences

Published: January 23, 2026

Integrative Transcriptomic and Proteomic Profiling Identifies S100P as a Potential Functional Biomarker for Sessile Serrated Lesions.

Integrative Transcriptomic and Proteomic Profiling Identifies S100P as a Potential Functional Biomarker for Sessile Serrated Lesions.

Journal: Digestive diseases and sciences

Published: January 21, 2026

Targeting the Extracellular Signal-Regulated Kinase 5-Cellular Jun-Vimentin Axis to Inhibit Epithelial-Mesenchymal Transition and Metastasis in Patients with Triple-Negative Breast Cancer.

Targeting the Extracellular Signal-Regulated Kinase 5-Cellular Jun-Vimentin Axis to Inhibit Epithelial-Mesenchymal Transition and Metastasis in Patients with Triple-Negative Breast Cancer.

Journal: International journal of medical sciences

Published: January 18, 2026

SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells.

SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells.

Journal: Frontiers in bioscience (Landmark edition)

Published: July 29, 2025

Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival.

Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival.

Journal: OncoTargets and therapy

Published: July 21, 2025

Decreased plasma level of C-type lectin-like receptor 2 (CLEC-2) in patients with breast cancer.

Decreased plasma level of C-type lectin-like receptor 2 (CLEC-2) in patients with breast cancer.

Journal: International journal of medical sciences

Published: May 09, 2025

Analysis of the Yield of Intestinal Metaplasia Based on Biopsy Numbers and Follow-Up Endoscopy in a Large Series of Asian Patients With Barrett's Esophagus.

Analysis of the Yield of Intestinal Metaplasia Based on Biopsy Numbers and Follow-Up Endoscopy in a Large Series of Asian Patients With Barrett's Esophagus.

Journal: Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society

Published: March 22, 2025

Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells.

Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells.

Journal: Biomedicines

Published: March 16, 2025

Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma.

Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma.

Journal: Biomedicines

Published: March 12, 2025

Predominant Serrated Molecular Signature in Postcolonoscopy Colorectal Cancer: A Systematic Review and Meta-Analysis.

Predominant Serrated Molecular Signature in Postcolonoscopy Colorectal Cancer: A Systematic Review and Meta-Analysis.

Journal: The American journal of gastroenterology

Published: January 22, 2025

Showing 1-12 of 39

Last Updated: 09/26/2026